Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration

Journal of Nanobiotechnology

Volumn 14, Issue 1, 2016, Pages

  Muralidharan, Ranganayaki ^a,b   Babu, Anish ^a,b   Amreddy, Narsireddy ^a,b   Basalingappa, Kanthesh ^a,b   Mehta, Meghna ^a,b   Chen, Allshine ^b   Zhao, Yan Daniel ^b   Kompella, Uday B ^c   Munshi, Anupama ^a,b   Ramesh, Rajagopal ^a,b,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Stanton L Young Biomedical Research Center   (United States)

Author keywords

Folate; HuR; Lung cancer; Nanoparticle; Oncoprotein; SiRNA; Targeting

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; DIAGNOSIS; MOLECULAR BIOLOGY; NANOPARTICLES; NUCLEIC ACIDS; PARTICLE SIZE; PROTEINS;

FOLATE; LUNG CANCER; ONCOPROTEINS; SIRNA; TARGETING;

DISEASES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; CYCLIN D1; CYCLIN E; FOLATE RECEPTOR 1; HUMAN ANTIGEN R; LIPID; MESSENGER RNA; NANOPARTICLE; PROTEIN BCL 2; PROTEIN P27; RNA BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ELAV LIKE PROTEIN 1; ELAVL1 PROTEIN, HUMAN; FOLIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CCD16 CELL; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG UPTAKE; ENDOCYTOSIS; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; H1299 LUNG CANCER CELL LINE; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG CANCER; LUNG CANCER CELL LINE; LUNG FIBROBLAST; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RNAI THERAPEUTICS; SURFACE PROPERTY; CELL MOTION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL; DRUG DELIVERY SYSTEMS; ELAV-LIKE PROTEIN 1; FOLATE RECEPTOR 1; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; NANOPARTICLES; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84975316760     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-016-0201-1     Document Type: Article

References (57)

1. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4:327-38.
2. Sharma R, Sharma A. Multidrug resistance (MDR) in lung cancer: finding the holy grail of MDR reversal. J Cancer Sci Ther. 2012. doi: 10.4172/1948-5956.
3. Kim YD, Park TE, Singh B, Maharjan S, Choi YJ, Choung PH, et al. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine (Lond). 2015;10:1165-88.
4. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:419-26.
5. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, et al. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv. 2011. doi: 10.1155/2011/465845.
6. Sechler M, Cizmic AD, Avasarala S, Van-Scoyk M, Brzezinski C, Kelley N, et al. A non-small-cell lung cancer: molecular targeted therapy and personalized medicine-drug resistance, mechanisms, and strategies. Pharmacogenomics Pers Med. 2013;6:25-36.
7. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:0225-35.
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-92.
9. Wang J, Guo Y, Chu H, Guan Y, Bi J, Wang B, et al. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci. 2013;14:10015-41.
10. Miyata Y, Watanabe S-I, Sagara Y, Mitsunari K, Matsuo T, Ohba K, et al. High expression of HuR in cytoplasm, but not Nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer. Plos ONE. 2013;8:59095. doi: 10.1371/Journal.Pone.0059095.
11. Fialcowitz-White EJ, Brewer BY, Ballin JD, Willis CD, Tpth EA, Wilson GM. Specific protein domains mediate cooperative assembly of HuR oligomers on Au-Rich mRNA-destabilizing sequences. J Biol Chem. 2007;282:20948-59.
12. Ronkainen H, Vaarala MH, Hirvikoski P, Ristimaki A. Hur expression is a marker of poor prognosis in renal cell carcinoma. Tumor Biol. 2011;32:481-7.
13. Heinonen M, Bono P, Narko K, Chang S-H, Lundin J, Joensuu H, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005;65:2157-61.
14. Wang J, Wang B, Zhang C. Cytoplasmic Hur expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol. 2011;28:577-85.
15. Muralidharan R, Babu A, Basalingappa K, Mehta M, Munshi A, Ramesh R. Designing of tumor-targeted HuR siRNA nanoparticle as a therapeutic for lung cancer. In: Gandhi V, Mehta K, Grover RK, Pathak S, Aggarwal BB, editors. Multitargeted approach to the treatment of cancer. New York: Springer; 2015. p. 277-94.
16. Muralidharan R, Panneerselvam J, Chen A, Zhao YD, Munshi A, Ramesh R. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015;22:581-90.
17. Kakuguchi W, Kitamura T, Kuroshima T, Ishikawa M, Kitagawa T, Totsukawa Y, et al. HuR knockdown changes the oncogenic potential of oral cancer cells. Mol Cancer Res. 2010;8:520-8.
18. Babu A, Amreddy N, Muralidharan R, Munshi A, Ramesh R. Nanoparticle-mediated siRNA delivery for lung cancer treatment. In: Naik J, editor. Nano based drug delivery. Croatia: IAPC Publishing; 2015. p. 195-215.
19. Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, et al. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011;19:381-5.
20. Wang J, Lu Z, Wientjes G, Au JL-S. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492-503.
21. Lee J-M, Yoon T-J, Cho Y-S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013. doi: 10.1155/2013/782041.
22. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12:967-77.
23. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-52.
24. Cardoso AL, Simoes S, De Almeida LP, Pelisek J, Culmsee C, Wagner E, et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med. 2007;9:170-83.
25. Ramesh R, Ito I, Miyahara R, Saito Y, Wu Z, Mhashilkar AM, et al. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2004;23:850-7.
26. Ito I, Ji L, Gopalan B, Tanaka F, Saito Y, Branch CD, et al. DOTAP:CHOLESTEROL liposome mediated delivery of the 3p gene FUS1 inhibits growth of human lung cancer in vivo. Cancer Gene Ther. 2004;1:733-9.
27. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, et al. Phase I clinical trial of systemically administered Tusc2(Fus1)-nanoparticles mediating functional gene transfer in humans. PLoS ONE. 2012. doi: 10.1371/Journal.Pone.0034833.
28. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 1996;386:243-6.
29. Podesta JE, Kostarelos K. Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery. In: Duzguneş Nejat, editor. Methods in Enzymology. Burlington: Academic; 2009. p. 343-54.
30. Goldenthal KL, Pastan I, Willingham MC. Initial steps in receptor-mediated endocytosis. The influence of temperature on the shape and distribution of plasma membrane clathrin-coated pits in cultured mammalian cells. Exp Cell Res. 1984;152:558-64.
31. Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 2011;9:648.
32. Guo J, Li M, Meng X, Sui J, Dou L, Tang W, et al. Mir-291b-3p induces apoptosis in liver cell line NCTC1469 by reducing the level of RNA-binding protein HuR. Cell Physiol Biochem. 2014;33:810-22.
33. Ito I, Began G, Mohiuddin I, Saeki T, Saito Y, Branch CD, et al. Increased uptake of liposomal-DNA complex by lung metastases following intravenous administration. Mol Ther. 2003;7:409-18.
34. Ishimaru D, Ramalingam S, Sengupta TK, Bandyopadhyay S, Dellis S, Tholaikunnel BG, et al. Regulation of Bcl-2 expression by HuR in Hl60 leukemia cells and A431 carcinoma cells. Mol Cancer Res. 2009;7:1354-66.
35. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, et al. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT activation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS ONE. 2015;10:e0131833.
36. Kurosu T, Ohga N, Hida Y, Maishi N, Akiyama K, Kakuguchi W, et al. HuR keeps an angiogenic switch on by stabilizing mRNA of VEGF and COX-2 in tumor endothelium. Br J Cancer. 2011;104:819-29.
37. Panneerselvam J, Jin J, Shanker M, Lauderdale J, Bates J, Wang Q, et al. Il-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS ONE. 2015. doi: 10.1371/Journal.Pone.0122439.
38. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, et al. In vitro and in vivo effects of polyethylene glycol (Peg)-modified lipid in DOTAP/Cholesterol-mediated gene transfection. Int J Nanomed. 2010;5:371-83.
39. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. BBA-Biomembranes. 2002;1564:343-8.
40. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16:415-23.
41. Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, et al. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res. 2016;76:1549-59.
42. Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, et al. HuR Contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol Cancer Res. 2016. [Epub ahead of print].
43. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012. doi: 10.3402/Nano.V3i0.18496.
44. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65:121-38.
45. Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in Mcf-7 breast cancer cells. Cancer Res. 2006;66:7948-56.
46. Kullmann M, Gopfert U, Siewe B, Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. Genes Dev. 2002;16:3087-99.
47. Choi YJ, Anders L. Signaling through cyclin D-dependent Kinases. Oncogene. 2014;13:1890-903.
48. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007;8:149-60.
49. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7:831-6.
50. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-37.
51. Morosétti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995;86:1924-30.
52. Shanker M, Kumar M, Garcia A, Scott A, Bekele N, Roth J, et al. HuR: a mRNA-binding protein as target for cancer therapy. Cancer Res. 2008;68:115.
53. Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep. 2011;26:237-45.
54. Dormoy-Racelet V, Menard I, Clair E, Kurban G, Mazroui R, Marco SD, et al. The RNA-binding protein HuR promotes cell migration and cell invasion by stabilizing the Β-Actin mrna in AU-Rich-element-dependent manner. Mol Cell Biol. 2007;15:5365-80.
55. Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. 2001;3:337-50.
56. Amreddy N, Muralidharan R, Babu A, Mehta M, Johnson EV, Zhao YD, et al. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomed. 2015;10:6773-88.
57. Panneerselvam J, Shanker M, Jin J, Branch CD, Muralidharan R, Zhao DY, et al. Phosphorylation of interleukin (IL)-24 is required for its anticancer activity. Oncotarget. 2015;18:16271-86.